Dreger, Peter
Michallet, Mauricette
Bosman, Paul
Dietrich, Sascha
Sobh, Mohamad
Boumendil, Ariane
Nagler, Arnon
Scheid, Christof
Cornelissen, Jan
Niederwieser, Dietger http://orcid.org/0000-0002-4737-1103
Müller, Lutz
Vandenberghe, Elizabeth
Scortechini, Ilaria
Schoemans, Helene http://orcid.org/0000-0002-7568-8239
Andersen, Niels S.
Finke, Jürgen
Russo, Domenico
Ljungman, Per http://orcid.org/0000-0002-8281-3245
Passweg, Jakob
van Gelder, Michel
Durakovic, Nadira
Labussiere-Wallet, Helene
Berg, Tobias
Wulf, Gerald
Bethge, Wolfgang
Bunjes, Donald
Stilgenbauer, Stefan
Canepari, Maria Elisa
Schaap, Michel
Fox, Christopher P.
Kröger, Nicolaus
Montoto, Silvia
Schetelig, Johannes
Article History
Received: 25 February 2018
Revised: 7 April 2018
Accepted: 10 April 2018
First Online: 4 May 2018
Compliance with ethical standards
:
: PD: Consultancy for AbbVie, Roche and Janssen; consultancy and speakers bureau for Gilead; speakers bureau for Kite Pharma. MM: Consultancy and Speakers bureau for Sanofi, MSD, Octapharma, Pfizer, MAATPharma, Novartis. CPF: Consultancy, speakers bureau and travel grants from Janssen. MvG: Consultancy for Gilead and Janssen; speakers bureau for Abbvie, Gilead, Janssen and Roche; Educational support from Gilead. TB: Consultancy for Riemser; travel grants from Astellas, Alexion, Celgene, Abbvie. SS: Consultancy, Speakers bureau, travel grants and research funding from AbbVie, Amgen, Celgene, Gilead, GSK, Roche, Janssen, Novartis, Pharmacyclics. SM: Speakers bureau for Roche; travel grant from Gilead. JS: Consultancy and Speakers bureau for AbbVie, Gilead, Janssen, Roche, Sanofi; research funding from Genzyme, Sanofi, GSK, Novartis, Abbvie. The remaining authors declare that they have no conflict of interest.